Black Hawk Acquisition signs Meteora financing agreements tied to Vesicor merger
On September 22, 2026, Black Hawk Acquisition Corp (BKHA) and Vesicor Therapeutics entered into a series of financing agreements with Meteora Select Trading Opportunities Master, LP, in connection with their previously announced business combination. The agreements include a forward purchase, a non-redemption arrangement, a standby equity purchase agreement and a registration rights agreement, and they could increase the number of shares outstanding after the merger closes.
Key points
- Forward purchase agreement covers up to 1,350,000 shares, with an initial price equal to the per-share redemption price and a reset price initially set at $10.00 per share.
- Non-redemption agreement covers up to 2,124,077 ordinary shares; the Company would pay Meteora cash from the trust account at closing, equal to the final redemption price less $0.75 per share.
- Standby equity purchase agreement lets PubCo sell up to $200.0 million of common stock to Meteora over a commitment period generally lasting 36 months; the commitment fee is 0.50% of that amount.
- Registration rights agreement requires an initial resale registration statement within 60 calendar days after closing, covering at least the greater of 10,000,000 shares and 300% of shares issuable on note conversion.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.